Welcome to our dedicated page for MDxHealth SA SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
MDxHealth SA reported preliminary 2025 revenue of about $109 million, with fourth quarter revenue of about $30.5 million, reflecting year-over-year growth of 21% and 23%, respectively. In the quarter, the company billed 11,201 tissue-based and 27,486 liquid-based units, while full-year volumes reached 49,180 tissue-based and 71,920 liquid-based units, with especially strong liquid-based growth. Year-end cash was $29.0 million.
For 2026, MDxHealth guides revenue to $137–140 million, implying growth of about 26–28%, and targets an adjusted EBITDA margin run rate of 10% exiting 2026. The company also amended the earnout related to its 2022 GPS acquisition from Exact Sciences, deferring payments into three installments of $15.0 million in 2026, $18.0 million in 2027, and $21.5 million in 2028, and agreed to issue warrants for 3 million shares at an exercise price of $5.265 per share.
MDxHealth SA submitted a Form 6-K as a foreign private issuer to provide its 2025 Interim Report to investors. The interim report is attached as Exhibit 99.1 and contains the company’s detailed mid-year financial and operational information.
The company also formally confirms the accuracy of its previously released preliminary financial results that were furnished in a prior Form 6-K on August 5, 2025. The interim report is incorporated by reference into MDxHealth’s existing shelf registration statements on Form F-3, meaning those registration statements now include the latest interim information.